![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0003.png)
allied
academies
Page 21
Notes:
July 05-06, 2019 | Paris, France
Pharmaceutics and Advanced Drug Delivery Systems
2
nd
International Conference and Exhibition on
Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9
The influence of eudragits and PVP on the modified release of Furosemide
Marilena Vlachou, Angeliki Siamidi
and
Efthimia Geraniou
National and Kapodistrian University of Athens, Greece
F
urosemide 4-chloro-2-[(furan-2-ylmethyl) amino]-5-
sulfamoylbenzoic acid, is widely used as diuretic for
the treatment of high blood pressure and fluid retention
caused by heart failure or kidney disease. It is considered
as a loop diuretic, which inhibits the re-absorption of
sodium in the thick ascending limb of the loop of Henle
and it is effective in cases of renal failure. Furosemide is
characterized by a low solubility and poor permeability
in the upper GI tract, thus is classified in the BCS system,
as an IV drug. However, with the entrance of furosemide
in intestinal fluids a rapid release of the drug occurs,
which is accompanied by an increased natriuretic and
diuretic effect, causing displeasure to the patients. As
a result, a slow release formulation would be probably
preferred by patients, because of a lower initial diuretic
effect and a more extended duration of action. To this
end, we extended our previous research on the modified
release of this drug by using PVP and different grades of
Eudragit polymers. Eudragits are commonly used when it
is required to modify the release rate, and the different
grades of polymer offer a variety of physicochemical
properties depending on what is desired. These excipients
were formulated, in the context of this work, in matrix
systems for oral administration.
Speaker Biography
Marilena Vlachou is an Assistant Professor at the National and
Kapodistrian University of Athens (NKUoA), Greece. After obtaining
her Pharmacy degree from NKUoA, she conducted research related to
novel Pharmaceutical Technology techniques at the University of Rhode
Island, USA, as a Visiting Research Scientist. She then moved back to
Greece to pursue PhD studies on Physical Pharmacy/Pharmaceutical
Technology. In her capacity as a member of staff of NKUoA, she teaches
two undergraduate courses and one postgraduate, all related to the
field of Pharmaceutical Technology. She has co-authored the textbook
entitled “Pharmaceutical Technology I: Principles of Physical Pharmacy
and Nanotechnology”, 2007, Parisianou Editions, Athens-Greece,
(ISBN: 978-960-394-487-4), and has presented her research work in
more than fifty International and Domestic Scientific Conferences and
has published more than thirty five articles in peer-reviewed Journals.
She is a member of Greek Pharmaceutical Society, Greek Society of
Pharmaceutical Technology and Greek Society of Cosmetology.
e:
vlachou@pharm.uoa.grMarilena Vlachou et al.
, Asian J Biomed Pharmaceut Sci, | ISSN: 2249-622X
Volume 9